Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03885778
NCT03885778CompletedPhase 4

An Open Label, Randomized, 2-sequence, 2-period, Single-dose Cross-over Design Clinical Trial to Evaluate the Food Effect on Pharmacokinetics of BESIVO in Healthy Adult Volunteers

IlDong Pharmaceutical Co Ltd1 site in 1 country15 target enrollmentStarted: January 13, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
15
Locations
1
Primary Endpoint
Area Under the Curve [AUC] of of Besifovir
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To investigate the PK characteristics and the effect of food on the PK in healthy volunteers who receive Besifovir dipivoxil in fed versus fasted condition

Detailed Description

A randomized, open-label, 2-sequence, 2-period, single-dose cross-over clinical trial to investigate the pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of Besifovir dipivoxil in healthy volunteers

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
19 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
  • •Age of 19 to 50 years and Body Mass Index [BMI] of 18.0 to 27.0 kg/m2
  • •Subject with no congenital or chronic disease and no medically symptomatic findings
  • •Subject must be healthy on the basis of vital signs, 12-lead ECG, physical examination and laboratory test performed at screening.

Exclusion Criteria

  • •Medical history
  • •History of clinically significant of gastrointestinal system, hepatic portal system, cardiovascular system, respiratory system, endocrine system, renal-urinary system, immunologic system, musculoskeletal system, neurological, or psychiatric system, blood tumor, ophthalmology, otolaryngology disorder(as determined by the Investigator).
  • •Prior history of a gastrointestinal disorder that may affect drug absorption, distribution, metabolism and elimination (e.g., Crohn's disease, ulcer or surgery, except for simple appendectomy or hernia surgery)
  • •Clinical tests
  • •Systolic Blood Pressure: lower than 90mmHg or higher than 140mmHg, Diastolic Blood Pressure: lower than 60mmHg or higher than 180mmHg
  • •Repeated measurement of laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • •Aspartate transaminase [AST] or alanine aminotransferase [ALT] > 1.5 x upper limit of normal range
  • •Total bilirubin > 1.5 x upper limit of normal range
  • •estimated glomerular filtration rate [eGFR] < 75mL/min/1.73m2 (using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equations)
  • •Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C virus(HCV), anti-Human immunodeficiency virus(HIV) or Syphilis reagin test
  • •Subjects with clinically significant abnormalities in 12-lead ECG determined by repeated measurement
  • •Allergy, hypersensitivity, and drug abuse
  • •History of significant hypersensitivity to Besifovir, this drug ingredient or other drug (e.g., aspirin, antibiotics)
  • •History of clinically significant allergy/hypersensitivity
  • •A history of drug abuse (especially, central nervous system agents such as sleeping pills, central painkillers, opiates or psychotropic drugs) or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs(amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines)
  • •The contraindication of comedication drugs and diets
  • •Subject who has taken drugs for drug metabolizing enzyme induction and inhibition within 1 month before the first adminstration
  • •Subject who has taken other ethical the count [ETC] drugs (including prescription of herbal medicine) within the last 14 days, or over the count [OTC] drugs within the last 10 days (as determined by the Investigators)
  • •Subject who has taken abnormal meals (eg. ingestion of grapefruit juice, garlic extract, broccoli, and kale) which can affect to drug absorption, distribution, metabolism, and excretion [ADME] and supplements within 7 days prior to administration of trial medication and during the trial
  • •Subject who has participated in any other bioequivalence study or clinical trial and taken other investigational products within 3 months prior to the first adminstration
  • •Donation and receipt of blood
  • •Subject who had whole blood donation within 2 months prior to administration of trial medication
  • •Subject who had component blood donation or transfusion within 1 months prior to administration of trial medication
  • •Pregnant and contraception
  • •Pregnant, positive of pregnancy test or breast-feeding women
  • •Subjects who do not use medically acceptable contraception during the entire period of the trial
  • •Use of intrauterine device
  • •Use of intercourse contraceptive (male or female) and spermicide
  • •Tubectomy, canal ligation and hysterectomy
  • •Other criteria
  • •Use of Xanthine (eg. green tea, coffee, black tea, coke, cocoa, chocolate, energy drink, and etc.) within 3 days prior to administration of trial medication and during the trial
  • •Intake of more than 30g of alcohol per day or who can't abstain from alcohol during the trial
  • •Subjects who can't quit smoking during the trial
  • •Subjects who are considered to be unacceptable in this study under the opinion of the investigator.

Arms & Interventions

A-fasted dosing followed by fed dosing

Experimental

Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing

Intervention: Besifovir dipivoxil (Drug)

B-fed dosing followed by fasted dosing

Experimental

Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing

Intervention: Besifovir dipivoxil (Drug)

Outcomes

Primary Outcomes

Area Under the Curve [AUC] of of Besifovir

Time Frame: Up to 24 Hours after study drug administration

Area under the plasma concentration versus time curve for Besifovir

Maximum Observed Plasma Concentration [Cmax] of Besifovir

Time Frame: Up to 24 Hours after study drug administration

The Cmax is the maximum observed plasma concentration.

Secondary Outcomes

  • Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Besifovir(Up to 24 Hours after study drug administration)
  • Time to reach the Cmax [Tmax] of Besifovir(Up to 24 Hours after study drug administration)
  • Apparent terminal half-life [t1/2](Up to 24 Hours after study drug administration)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male VolunteersHealthy
NCT02529800Hanmi Pharmaceutical Company Limited24
Withdrawn
Phase 1
Healthy Volunteer Study Comparing Tablet and Capsule FormulationsFibrosis
NCT04001998Blade Therapeutics
Completed
Phase 1
Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted StateObesity
NCT00828724Eisai Inc.24
Completed
Phase 1
A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric FormulationHealthy Volunteers
NCT03434977Takeda12
Completed
Phase 1
A Food Effect Phase I Study of the Volitinib in Healthy SubjectsFood EffectHealth Subjects
NCT02017236Hutchison Medipharma Limited25